Department of Hepatic Surgery and Liver Transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute of Sun Yat-Sen University, Organ Transplantation Research Center of Guangdong Province, Guangzhou 510630, China.
Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
Hepatobiliary Pancreat Dis Int. 2017 Oct 15;16(5):480-486. doi: 10.1016/S1499-3872(17)60052-3.
With the expansion of surgical criteria, the comparative efficacy between surgical resection (SR) and liver transplantation (LT) for hepatocellular carcinoma is inconclusive. This study aimed to develop a prognostic nomogram for predicting recurrence-free survival of hepatocellular carcinoma patients after resection and explored the possibility of using nomogram as treatment algorithm reference.
From 2003 to 2012, 310 hepatocellular carcinoma patients within Hangzhou criteria undergoing resection or liver transplantation were included. Total tumor volume, albumin level, HBV DNA copies and portal hypertension were included for constructing the nomogram. The resection patients were stratified into low- and high-risk groups by the median nomogram score of 116. Independent risk factors were identified and a visually orientated nomogram was constructed using a Cox proportional hazards model to predict the recurrence risk for SR patients.
The low-risk SR group had better outcomes compared with the high-risk SR group (3-year recurrence-free survival rate, 71.1% vs 35.9%; 3-year overall survival rate, 89.8% vs 78.9%, both P<0.001). The high-risk SR group was associated with a worse recurrence-free survival rate but similar overall survival rate compared with the transplantation group (3-year recurrence-free survival rate, 35.9% vs 74.1%, P<0.001; 3-year overall survival rate, 78.9% vs 79.6%, P>0.05).
This nomogram offers individualized recurrence risk evaluation for hepatocellular carcinoma patients within Hangzhou criteria receiving resection. Transplantation should be considered the first-line treatment for high-risk patients.
随着手术标准的扩大,肝切除术(SR)与肝移植(LT)治疗肝细胞癌的疗效比较尚无定论。本研究旨在为接受切除术的肝细胞癌患者开发一种预测无复发生存率的预测列线图,并探讨将列线图用作治疗算法参考的可能性。
从 2003 年到 2012 年,纳入了 310 名符合杭州标准的肝细胞癌患者,这些患者接受了切除术或肝移植治疗。总肿瘤体积、白蛋白水平、HBV DNA 拷贝数和门静脉高压被纳入构建列线图。将切除术患者按列线图评分中位数 116 分为低危和高危组。使用 Cox 比例风险模型确定独立风险因素,并构建一个直观的列线图,以预测 SR 患者的复发风险。
与高危 SR 组相比,低危 SR 组的结果更好(3 年无复发生存率,71.1% vs 35.9%;3 年总生存率,89.8% vs 78.9%,均 P<0.001)。高危 SR 组的无复发生存率较差,但与移植组的总生存率相似(3 年无复发生存率,35.9% vs 74.1%,P<0.001;3 年总生存率,78.9% vs 79.6%,P>0.05)。
该列线图为接受切除术的符合杭州标准的肝细胞癌患者提供了个体化的复发风险评估。对于高危患者,应考虑将移植作为一线治疗。